Zongertinib demonstrates promising efficacy in patients with HER2-mutant non-small cell lung cancer
The HER2-specific tyrosine kinase inhibitor zongertinib was well tolerated and demonstrated promising efficacy in patients with HER2 mutation-positive non-small cell lung cancer, meeting the primary endpoint of the Beamion ...
Sep 9, 2024
0
0